Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra

SALT LAKE CITY, July 28, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that the company has launched a new enhancement that is now available on its Vectra test report. The new test report provides an individualized estimate of a patient’s one-year risk of rapid radiographic progression (RP). The RP result in every report is personalized based on the patient’s age, gender and adiposity. 

“We previously presented data demonstrating that Vectra is the best single predictor of joint damage. Inclusion of information on RP risk in the Vectra test report now gives clear insight into both the patient’s current rheumatoid arthritis (RA) inflammation and the future risk of joint damage,” said Mark S. Verratti, president of Myriad Neuroscience and Myriad Autoimmune. “With this new product enhancement, Vectra as a prognostic tool can help further guide medical management decisions for patients with RA.”
In a combined analysis of patients from three studies, 42 percent of patients thought to be in low or moderate disease activity assessed by a traditional disease activity measure were in high disease activity as measured by Vectra, and thus were at risk of irreversible joint damage within one year. Each patient will receive an individualized percentage risk prediction for radiographic progression within one year (see Example 1 below), helping physicians and patients make treatment decisions.

To view Example 1: The Vectra Score correlates to the risk of radiographic progression, please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/1ed33a2f-4c29-4cbb ...

RA is an inflammatory autoimmune disease that attacks a patient’s joints and often affects other organ systems.  RA is a contributing condition that leads to increased disability, significant morbidity, increased mortality and financial burden.  Lost productivity associated with RA is substantial, with approximately 20-70 percent of individuals working at the time of their RA diagnosis were disabled after seven to 10 years. RA affects roughly more than one million people in the United States. The Vectra Score measures the concentrations of 12 serum biomarkers and an algorithm is applied to these biomarker concentrations to calculate a disease activity score on a scale of 1 to 100.  Vectra Disease Activity Levels are as follows: Green = Low: 1 to 29, Orange = Moderate: 30 to 44, Red = High: 45 to 100.  The risk of RP is shown as a function of Vectra Score. The definition of RP is a 1-year total Sharp score change of >5 units. Increased risk of RP means a greater chance of irreversible joint damage.